Cyberwrite Named a 2018 Cool Vendor in Insurance by Gartner for Its Cyberrisk Profiling Technology
Cyberwrite today announced it has been included in the list of “Cool Vendors” in the “Cool Vendors in Insurance”1 by Gartner, Inc. The InsurTech innovator has been recognized for its cyberrisk profiling technology for cyber insurance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180516005214/en/
In the report Gartner writes, “Gartner's Cool Vendors in insurance apply a broad range of emerging technologies to provide innovative products and services and support new business models. Life and P&C insurance CIOs can use this research to keep themselves and their business peers ahead of the competition.”
Cyberwrite’s cloud-based SaaS solution gives insurers and brokers unique insights that enable them to tailor cyber insurance policies to meet the specific needs and budget of individual small and midsized businesses (SMBs). The solution is based on machine learning technology for translating raw cyber risk data into cyber coverage risk scores and financial impact estimations.
Cyberwrite enables coverage to be tailored to the specific risks of SMB’s, rather than the “one size fits all” approach currently offered. The solution is already being used by some of the world’s largest insurers, with reports run so far for over 50,000 companies globally.
Because Cyberwrite profiles and analyzes the cyber insurance risk of businesses in real time and on demand, it helps both insurers and their customers to understand the probability and financial impact of a cyber event for that specific business. This is presented in a one-page, simple to understand report, which serves insurers and brokers when they sell and underwrite cyber policies as well as business owners so they can purchase the right coverage. It is especially useful and clear for those who are not cyber experts.
In addition, insurance companies integrate Cyberwrite’s data into their system using Cyberwrite’s APIs for underwriting and catastrophe modelling purposes.
"Cyber insurance policies offered to small and midsize businesses are typically very broad and untailored, resulting in businesses paying extra for unneeded coverage while not being covered for the actual risks they face, and we are out to change this,” said Nir Perry, CEO, Cyberwrite. “We are very proud to be included in the prestigious Gartner report. We believe that Cyberwrite is set to shake things up in the coming years for the insurance industry.”
According to the US National Cyber Security Alliance 60 percent of small companies are unable to sustain their businesses six months after a cyber attack.
“Cyber insurance is becoming essential to businesses as the only product that compensates them after an attack, when technology cannot provide total protection. We expect high demand for this type of insurance among small and mid-size businesses because of the high and growing number of damaging cyber attacks,” added Perry. Allianz projects the cyber insurance market is set to grow to $20B in annual premiums in the next 7 years.
Cyberwrite is one of only four insurtech companies globally to be recognized by Gartner, as a Cool Vendor, whose insurtech database covers more than 1,000 startups.
¹Gartner, Cool Vendors in Insurance, Sham Gill, Kimberly Harris-Ferrante, Jeff Haner, Laurie Shotton, Richard Thomas Natale, Juergen Weiss, 26 April 2018
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Cyberwrite was founded in 2016 by a team of cyber risk experts and insurance veterans to address the $20B market of cyber insurance.
The company has customers in the United States and Europe and is backed by Austrian venture capital fund SpeedInvest, as well as senior insurance executives and angel investors from the United States and Israel. Among the company's advisors are Shmulik Regev, one of the founders of Trusteer and Inbar Raz, a thought leader and speaker in cyber intelligence research. Visit Cyberwrite at www.cyberwrite.com or on LinkedIn and Twitter.
Kesselring Communications for Cyberwrite
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aroma Bit to Develop Smartphone Embeddable Ultra-compact Silicon CMOS Based Smell Sensor That Has Dog Nose Equivalent Resolution in 1mm Squared Die Size23.7.2019 04:30:00 EEST | Press release
Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/ Picture of 1mm squared die of silicon CMOS based smell sensor, with dog nose equivalent ~1,200 sensor pixels (Photo: Business Wire) Aroma Bit: http://www.aromabit.com Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Micro
Logitech Delivers a Strong Start to Fiscal Year 2020 with Robust Sales and Profit Growth23.7.2019 04:00:00 EEST | Press release
Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the first quarter of Fiscal Year 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005781/en/ Logitech delivers a strong start to Fiscal Year 2020 with robust sales and profit growth. (Graphic: Business Wire) Q1 sales were $644 million, up 6 percent in US dollars and 9 percent in constant currency, compared to Q1 of the prior year. Q1 GAAP operating income grew 46 percent to $47 million, compared to $32 million in the same quarter a year ago. Q1 GAAP earnings per share (EPS) grew 17 percent to $0.27, compared to $0.23 in the same quarter a year ago. Q1 non-GAAP operating income grew 11 percent to $67 million, compared to $61 million in the same quarter a year ago. Q1 non-GAAP EPS grew 15 percent to $0.39, compared to $0.34 in the same quarter a year ago. Cash flow from operations was $37 million, compared to $12 million in the sa
Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance22.7.2019 19:00:00 EEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs). The use of Biktarvy in patients with known drug resistance is investigational. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “These data presented at IAS provide new information about the treatment of HIV among women and patients with known drug resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “The studies further demonstrate the potential for Biktarvy to be an
IBC Celebrates Young Talent in the Industry22.7.2019 18:36:00 EEST | Press release
The media, entertainment and technology industry is changing. Attitudes are shifting, the next generation is consuming content differently to any before them and diverse and exciting content is being created to meet that demand in innovative formats. Driving this change is a new wave of industry talent, honoured at IBC with the first IBC Young Pioneer Award. Recognising the brightest, newest talent in the industry, this award will go to someone who has made a real impact with their passion, ambition and commitment and is making an outstanding contribution to our industry. “What we were looking for in the shortlist was, most importantly, real talent, a stand-out individual making a real difference in the industry,” said David Levine, VP, Programming - Kids, Europe & Africa/UK & Ireland, The Walt Disney Co. Ltd and Chair of the Judging Panel. “But we were also looking for a lasting legacy, for the Young Pioneer to be a leader today and a media guru of the future.” The call for entries so
Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV22.7.2019 18:00:00 EEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function. The Phase 1b data demonstrate the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load in vivo. In addition, Gilead presented preclinical data demonstrating that resistance to GS-6207 in vitro did not lead to resistance to other classes of drugs used in the treatment of HIV. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. GS-6207 is an investigational long-acting antiretroviral agent that can be delivered subcutaneously. GS-6207 recently received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) as a potential therapy for heavily treatment-experienced people living with multi-drug resistant HIV. GS-6207 acts in a novel way compared with current
Pacific Drilling Appoints James W. Harris as Chief Financial Officer22.7.2019 16:42:00 EEST | Press release
Pacific Drilling S.A. (NYSE: PACD), one of the world’s leading deepwater drilling contractors, today announced that Pacific Drilling’s Board has appointed James W. Harris to serve as the Company’s Senior Vice President and Chief Financial Officer. Mr. Harris replaces Mr. Johannes (John) P. Boots, who, as previously announced, mutually agreed with the Company to step down from his position to pursue other opportunities. Mr. Harris has more than 30 years of experience in the energy industry in a variety of financial leadership, strategic and business planning roles. He most recently served as Executive Vice President, Drilling & Subsea for Forum Energy Technologies, Inc., having previously served Forum as Chief Financial Officer for 12 years. Bernie Wolford, the Company’s Chief Executive Officer, stated, “We sincerely appreciate the many contributions that John has made during his nearly 10-year tenure with Pacific Drilling and we wish him all the best in his future endeavors.” “We are e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom